Journal of Vascular and Interventional Radiology

The VasQ™ External Support Now FDA Cleared for Use in Creating Arteriovenous Fistulas

Retrieved on: 
Wednesday, September 27, 2023
Infection, Surgeon, Lamination, Freedom, De novo, Hospital, CVC, Ioctl, National Institutes of Health Clinical Center, Dialysis, TEL, Journal, Patient, Physician, Arteriovenous fistula, Journal of Vascular and Interventional Radiology, FDA, AVF, Vascular surgery, Safety, Fistula, Medical imaging

TEL AVIV, Israel, Sept. 27, 2023 /PRNewswire/ -- Laminate Medical Technologies (Laminate) has announced their flagship device, the VasQ External Vascular Support, has been cleared by the FDA for use to create arteriovenous fistulas (AVFs) for dialysis access.

Key Points: 
  • TEL AVIV, Israel, Sept. 27, 2023 /PRNewswire/ -- Laminate Medical Technologies (Laminate) has announced their flagship device, the VasQ External Vascular Support, has been cleared by the FDA for use to create arteriovenous fistulas (AVFs) for dialysis access.
  • No serious adverse event associated with the device was reported over the 2-year study.
  • Additional analysis comparing VasQ patients against claims data for traditional AVFs created by the same surgeons in the study reported statistically superior rates of functional success (confirmed use of the AVF for dialysis) and reduced need for additional procedures.
  • VasQ is a nitinol-based device implanted around the artery and vein during the surgical creation of an arteriovenous fistula.

Precision IR Performs First Outpatient Y-90 Radioembolization Procedure in an Office-Based Lab in Michigan

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Health, Radiology, Practice Management, Oncology, P.C, Osteoarthritis, Radiation, Y-90, Hepatic artery proper, Half-life, Neoplasm, Liver tumor, Journal of Vascular and Interventional Radiology, Cancer, Prostate, Precision, Liver cancer, Blood, Knee pain, Interventional radiology, Go (programming language), Hospital, Patient, Observation, Growth, OBL, Trauma, Liver, Medical imaging

Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.

Key Points: 
  • Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.
  • To perform the procedure in an OBL setting, the facility must have the required imaging equipment and procedure rooms, along with the processes to safely handle nuclear materials.
  • Clinical experience has shown that the vast majority of Y-90 radioembolization patients do not need to be kept overnight for observation; they are able to return home shortly after the two-hour procedure.
  • “But cancer patients appreciate the option of having their treatment in a more relaxed and customer-focused environment.”
    Precision IR is now scheduling Y-90 radioembolization patients.

IceCure Medical Reports First Quarter 2023 Financial & Operational Results

Retrieved on: 
Monday, May 22, 2023
Momentum, Journal of Vascular and Interventional Radiology, Insurance, Society, Marketing, Neoplasm, Common stock, Cryoablation, Catheter, Pain, Interventional radiology, Journal, Patent, Patient, Interventional oncology, Three Months, ICE3, Commercial use of space, Research, Course (education), Freezing, Paper, FDA, Conference, NMPA, Tel Aviv Stock Exchange, Interest, Conference call, National Medical Products Administration, Gynaecology, TASE, Webcast, CME, Endometriosis, Surgeon, Speech, Clinical trial, Woman, American Society of Breast Surgeons, Physician, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging, Birth control, Cryptocurrency, Broadcasting, Medtronic

Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses

Key Points: 
  • Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses
    CAESAREA, Israel, May 22, 2023 /PRNewswire/-- IceCure Medical Ltd. (the "Company" or "IceCure") (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.
  • We believe this momentum in the market is bolstered by a broader trend toward minimally invasive procedures," stated IceCure CEO Eyal Shamir.
  • Company's Ordinary Shares to Trade Exclusively on Nasdaq: IceCure announced its voluntary delisting from the Tel Aviv Stock Exchange ("TASE").
  • In the first quarter of 2023, sales increased in the U.S. and Europe relative to the same quarter last year.

New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE)

Retrieved on: 
Thursday, February 23, 2023
Beth Israel Deaconess Medical Center, Death, Safety, Journal of Vascular and Interventional Radiology, DVT, Society, Interventional radiology, PE, Embolism, Physician, JVIR, Recurrence, Inferior vena cava filter, PES, Risk, Health, Society of Interventional Radiology, Filter, Deep vein thrombosis, SIR, Journal, FDA, Radiology, Patient, Indiana University School of Medicine, Effectiveness, VTE, IVC, SVS, Society for Vascular Surgery, Coronary thrombosis, MS, FACS, Inferior vena cava, Pulmonary embolism, Birth control, Medical imaging, Nursing, MD, DRS

CHICAGO and FAIRFAX, Va., Feb. 23, 2023 /PRNewswire/ -- Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).

Key Points: 
  • PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers.
  • The study was conducted at 54 sites in the United States between Oct. 10, 2015, and March 31, 2019.
  • During that time, filters were implanted in 1,421 patients, of which 1,019 patients had an existing deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • Approximately half of the patients in the study had their filters removed within 3 months of placement without complication or recurrence of DVT or PE, according to study authors.

Hatch Medical Retained By EndoBar Solutions To Sell Embolotherapy System, Lamina™

Retrieved on: 
Tuesday, February 21, 2023
Toxicity, Doctor of Science, Medical director, Interventional radiology, Journal of Vascular and Interventional Radiology, Journal, Therapy, L.L.C, Safety, Medicare, Acquisition, Patient, News, Pressure, ROSA, Neoplasm, Principal, DRS, Weight loss, Doctor of Philosophy, Medical device, Pharmaceutical industry, MD

SANTA ROSA BEACH, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C.

Key Points: 
  • SANTA ROSA BEACH, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C.
  • ( www.hatchmedical.com ) announced recently that it has been retained by EndoBar Solutions, LLC to broker a strategic transaction related to its robotic embolization system, Lamina™.
  • The embolization market is exploding and the Lamina™ system provides superior delivery,” said Steven Hvozda, Principal of Hatch Medical.
  • Nicholas Kipshidze, MD, PhD, DSc, Chief Medical Officer and Medical Director of EndoBar Solutions, L.L.C.

Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer

Retrieved on: 
Tuesday, June 21, 2022
Doctor of Philosophy, TACE, Tirapazamine, Fever, FDA, Therapy, Journal, HCC, Safety, B cell, BCLC, Radiofrequency ablation, CEO, Liver, Survival, Tumor necrosis factor, Recurrence, Liver cancer, TATE, MD, GLOBE, Immunotherapy, Doxorubicin, Journal of Vascular and Interventional Radiology, Hepatocellular carcinoma, Patient, Abdominal pain, Neoplasm, Necrosis, ECG, Interventional radiology, TPZ, Medical imaging, Pharmaceutical industry

PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled “Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma,” establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).

Key Points: 
  • The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin.
  • The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization.
  • Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study.
  • A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.

Journal of Vascular and Interventional Radiology Impact Factor passes key milestone of 3

Retrieved on: 
Monday, July 6, 2020
Interventional radiology, Journal of Vascular and Interventional Radiology, Academic journals, Medicine, Health, Radiology

According to the Journal Citation Reports, published by Clarivate Analytics, JVIR's Impact Factor jumped 7% to 3.037 in 2019, up from 2.828 in 2018.

Key Points: 
  • According to the Journal Citation Reports, published by Clarivate Analytics, JVIR's Impact Factor jumped 7% to 3.037 in 2019, up from 2.828 in 2018.
  • "This continuing growth trajectory makes JVIR the commanding voice of IR scienceand the home of the highest-level IR research on its pages.
  • "The research published in JVIR provides the support for image-guided therapies that interventional radiologists need to improve the lives of their patients."
  • JVIR citations appeared in radiology, nuclear medicine, medical imaging and peripheral vascular disease journals.